OrganaBio Acquires Excellos Assets to Establish Bicoastal Cell Therapy Manufacturing Platform
The acquisition expands cGMP manufacturing, PBMC isolation and cryopreservation capabilities across the US to support cell therapy developers from preclinical to commercial stages.
Excellos | 16/05/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy